Results 171 to 180 of about 321,312 (283)

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

British Journal of Haematology, EarlyView.
Summary Bridging therapy (BT) prior to brexucabtagene autoleucel (brexu‐cel) in mantle cell lymphoma (MCL) is supported by limited evidence. Here, we report BT modality and outcome in 176 patients at 15 centres in the United Kingdom. BT was delivered to 90% (158/176), the majority receiving standard chemotherapy +/− radiotherapy (53%) (SD chemo +/− RT)
Maeve A. O'Reilly, William Wilson, Bernard Maybury, Andrea Kuhnl, Claire Roddie, Ben Uttenthal, Rod Johnson, Rajesh Alajangi, Thomas Creasey, Ahmed Abdulgawad, Carlos Gonzalez Arias, Sunil Iyengar, Graeme Ferguson, Katerina Panopoulou, Alison Delaney, Angharad Pryce, Lourdes Rubio, Ceri Jones, Jonathan Lambert, Shweta Gupta, Amrith Mathew, Shenbagaram Kasivisvanathan, Olateni Awofisayo, Shreyas Hanmantgad, Graham P. Collins, Caroline Besley, Frances Seymour, Robin Sanderson, Sridhar Chaganti   +28 more
wiley   +1 more source

Unheard Voices: Unmet Psychosocial Needs of Carers of Myeloma-A Service Evaluation Exploring Patient and Carer Perceived Benefits of Attending a Myeloma Support Group. [PDF]

EJHaem
Sweeney K, Bolger J, Niblock A.
europepmc   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

British Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu, Jui‐Feng Hsu, Jee‐Fu Huang, Yi‐Chang Liu   +3 more
wiley   +1 more source

Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies. [PDF]

Front Oncol
Cavo M, Bringhen S, Buda G, Di Raimondo F, Musto P, Offidani M, Petrucci MT, Zamagni E, Zambello R, Berruto F, Freddi R, La Malfa P.   +11 more
europepmc   +1 more source

Oral selinexor–dexamethasone for triple-class refractory multiple myeloma [PDF]

, 2019
al., et, Vij, Ravi
core   +1 more source

The Art of Deception: Multiple Myeloma Imitating Spondyloarthritis-A Case Report. [PDF]

Clin Case Rep
Khatri P, Subedi A, Dahal B, Shrestha G, Phuyal M, Adhikari R.   +5 more
europepmc   +1 more source

Super-resolution binding activated localization microscopy through reversible change of DNA conformation [PDF]

, 2018
Aleksander Szczurek, Christoph Cremer, Hans Knecht, Jurek Dobrucki, Sabine Mai, Udo Birk   +5 more
core   +1 more source

Multiple Myeloma [PDF]

Journal of the American Society of Nephrology, 2006
Stephen M, Korbet, Melvin M, Schwartz
openaire   +2 more sources

Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed‐methods study

British Journal of Haematology, EarlyView.
Summary Research in multiple myeloma increasingly relies on surrogate end‐points to expedite approvals, yet these may not reflect patient priorities. We conducted a mixed‐methods study to identify outcomes valued by patients and clinicians and compare them with end‐points used in randomized controlled trials (RCTs).
Maria Mainou, Thomas Karagiannis, Eirini Pagkalidou, Aris Liakos, Panagiotis Malandrakis, Evdoxia Hatjiharissi, Sofia Chissan, Evdokia Mandala, Oliver Van Oekelen, Efthymia Vlachaki, Maria Papaioannou, Evangelos Terpos, Ghulam Rehman Mohyuddin, Apostolos Tsapas   +13 more
wiley   +1 more source

Case Report: From multiple myeloma to plasmablastic lymphoma - a diagnostic dilemma in unraveling a rare transformation. [PDF]

Front Oncol
Shraim M, Salameh A, Karama A, Lihya MA.
europepmc   +1 more source